Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
AssigneeMerck Patent GmbH
InventorsJosef Straub, Eike Staub
Life of this patent
Estimating the term…
Abstract
A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan αv integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan αv integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.
Claims16
A method of treating a bone metastasis disease in a subject, wherein said subject is characterized by:
- a) a high level of one or more proteins in at least one body fluid of said subject, wherein said one or more proteins are selected from the group consisting of:
- DCN (UniProt ID:
- P07585),
- F5 (UniProt ID:
- P12259),
- ICAM3 (UniProt ID:
- P32942),
- PIGR (UniProt ID:
- P01833),
- STK17B (UniProt ID:
- 094768),
- STX1A (UniProt ID:
- Q16623), and
- TEK (UniProt ID:
- Q02763),
- and/or
- b) a low level of one or more proteins in at least one body fluid of said subject, wherein said one or more proteins are selected from the group consisting of:
- ANG (UniProt ID:
- P03950),
- IL1B (UniProt ID:
- P01584),
- LEPR (UniProt ID:
- P48357),
- MAP2K2 (UniProt ID:
- P36507),
- MAPK11 (UniProt ID:
- Q15759),
- RGMB (UniProt ID:
- Q6NW40), and
- TNFRSF17 (UniProt ID:
- Q02223);
- said method comprising:
- administering to said subject at least one pan αv integrin inhibitor;
- wherein a level of a specific protein of said one or more proteins in at least one body fluid of said subject is
- a) classified as high, if the level of the specific protein of said one or more proteins in said body fluid is at least 2% higher than a median threshold determined for the specific protein,
- and/or
- b) classified as low, if the level of the specific protein of said one or more proteins in said body fluid is at least 2% lower than said median threshold for the specific protein;
- and
- wherein a threshold or median threshold for the specific protein is determined from the body fluid of a plurality of subjects being part of a diseased subject population suffering from the bone metastasis disease.
Dependencies are inferred from the claim text.